

Region-Specific, Life-Threatening Diseases among International Travelers from Israel, 2004–2015

Chen Avni, Shmuel Stienlauf, Eyal Meltzer, Yechezkel Sidi, Eli Schwartz, Eyal Leshem

We characterized posttravel hospitalizations of citizens returning to Israel by summarizing the returning traveler hospitalization dataset of the national referral Center for Travel Medicine and Tropical Diseases at Sheba Medical Center in Israel. Of 722 hospitalizations, 181 (25%) infections were life-threatening; most would have been preventable by chemoprophylaxis and pretravel vaccination.

International travel, particularly to tropical regions and low-income countries, may be associated with the risk for acute illness and hospitalization (1). The Center for Travel Medicine and Tropical Diseases at Sheba Medical Center (SMC; Tel Hashomer, Israel) is the national referral center for travel-associated illness in Israel. We characterized posttravel hospitalizations of citizens returning to Israel by summarizing the SMC returning traveler hospitalization dataset.

The Study

We investigated all international travel-associated hospitalizations of citizens of Israel at SMC during 2004–2015. We excluded case-patients for whom the time interval between return from travel and symptom onset exceeded the known incubation period for the cause of hospitalization. When identified illness after travel leading to hospitalization was nonendemic to Israel and caused symptoms after a long incubation (e.g., leishmaniasis, schistosomiasis), patients were included regardless of the time interval since return. We defined nonspecified febrile illness as a febrile illness with an undetermined cause (2). We excluded hospitalized persons who had unspecified febrile illness when the interval between return from travel and disease onset exceeded 2 weeks, because of the lower certainty of association between travel and illness. We defined acute and potentially life-threatening tropical diseases as infectious diseases largely confined to tropical and subtropical areas

of the world that had an incubation period of >4 weeks and an estimated risk for death >5% within 4 weeks after symptom onset if left untreated (3).

We determined the country of disease acquisition by a history of travel to a single country or exposure to a single country during the incubation period for the cause of hospitalization. To put the number of hospitalizations for illness acquired in each destination country in context of the estimated number of Israelis traveling to that country, we extracted the number of Israeli citizen entries by country from the United Nations World Tourism Organization dataset (4). We compared continuous variables by using the Student *t*-test and compared categorical variables by using the χ^2 test. Statistical significance was set at $p < 0.05$. The SMC Institutional Review Board approved this study.

During 2004–2015, a total of 722 travelers returning to Israel were hospitalized (Table 1; online Technical Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/24/4/17-1542-Techapp1.pdf>). The median patient age was 33 years (interquartile range 26–50 years); 530 (73%) were male. By continent, 330 (46%) patients had traveled to Asia; 267 (37%) to Africa; and 73 (10%) to South America, Central America, and the Caribbean. The travel destination countries from which the highest number of travelers were hospitalized were India (116 [16%]), Thailand (106 [15%]), and Ethiopia (48 [7%]). In relative terms, several countries, mostly in Africa, had a high number of hospitalizations relative to the estimated number of entries by Israeli citizens (Figure; online Technical Appendix Table 2).

Overall, the most common causes of hospitalization were malaria (145 [20%]), dengue (74 [10%]), and enteric fever (59 [8%]). Among 145 hospitalized malaria patients, 86 (59%) tested positive for *Plasmodium falciparum*. For Asia, the most common causes of admission were dengue fever, enteric fever, and unspecified febrile illnesses; for Africa, the most common were malaria, unspecified febrile illnesses, and acute schistosomiasis; and for South America, Central America, and the Caribbean, the most common were dengue fever and leptospirosis.

Patients hospitalized for *P. falciparum* malaria ($n = 86$) were older than those positive for *P. vivax* ($n = 36$) (43 ± 14 y vs. 34 ± 12 y; $p < 0.01$) and were more likely to be business travelers (39 [45%])

Author affiliations: The Center for Travel Medicine and Tropical Diseases, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

DOI: <https://doi.org/10.3201/eid2404.171542>

Table 1. Characteristics of travel-associated hospitalizations of citizens of Israel at Sheba Medical Center, Israel, 2004–2015*

Category	Africa, n = 267	Asia, n = 330	South America, n = 43	Central America/ Caribbean, n = 30	North America/ Europe, n = 26	Other,† n = 26	Total, n = 722
Patient characteristics							
Sex							
M	226 (85)	219 (66)	28 (65)	20 (67)	21 (81)	16 (62)	530 (73)
F	41 (15)	111 (34)	15 (35)	10 (33)	5 (19)	10 (38)	192 (27)
Age, median (IQR)	41 (29–53)	29 (24–43)	24 (23–43)	29 (27–46)	55 (39–64)	27 (23–41)	33 (26–50)
Age ≥60 y	37 (14)	27 (8)	4 (9)	3 (10)	8 (31)	4 (15)	83 (11)
Category of travelers							
Tourism	154 (58)	313 (95)	41 (95)	29 (97)	23 (88)	26 (100)	586 (81)
Business travelers	93 (35)	17 (5)	2 (5)	1 (3)	3 (12)	0	116 (16)
Visiting friends or relatives	19 (7)	1 (<1)	0	0	0	0	20 (3)
Type of illness							
Potentially preventable	85 (32)	25 (8)	0	1 (3)	0	1 (4)	112 (16)
Febrile conditions							
Malaria							
<i>Plasmodium falciparum</i> ‡	82 (30)	4 (1)	0	0	0	0	86 (12)
<i>P. vivax</i>	23 (9)	7 (2)	3 (7)	0	0	3 (12)	36 (5)
<i>P. ovale</i>	8 (3)	0	0	0	0	0	8 (1)
<i>P. malariae</i>	7 (3)	0	0	0	0	0	7 (<1)
Unidentified malaria	6 (2)	2 (<1)	0	0	0	0	8 (1)
Dengue fever	4 (1)	59 (18)	2 (5)	8 (27)	0	1 (4)	74 (10)
Enteric fever							
<i>Salmonella enterica</i> serovar Typhi	2 (<1)	19 (6)	0	1 (3)	0	1 (4)	23 (3)
<i>S. enterica</i> ser. Paratyphi	0	36 (11)	0	0	0	0	36 (5)
Leptospirosis	1 (<1)	18 (5)	0	7 (23)	1 (4)	2 (8)	29 (4)
Pneumonia	10 (4)	11 (3)	0	1 (3)	5 (19)	1 (4)	28 (4)
Febrile diarrheal diseases	10 (4)	5 (2)	1 (2)	0	2 (8)	1 (4)	19 (3)
Acute schistosomiasis	16 (6)	3 (<1)	0	0	0	0	19 (3)
Influenza	0	7 (2)	0	0	0	1 (4)	8 (1)
Epstein–Barr virus	1 (<1)	6 (2)	1 (2)	0	0	0	8 (1)
Cytomegalovirus	4 (1)	2 (<1)	2 (5)	0	0	0	8 (1)
Amebic liver abscess	0	5 (2)	0	0	0	2 (8)	7 (<1)
Rickettsial diseases	3 (1)	3 (<1)	0	0	0	0	6 (<1)
Upper respiratory tract infection	4 (1)	1 (<1)	0	0	0	0	5 (<1)
Unspecified febrile illness	34 (13)	55 (17)	7 (16)	3 (10)	6 (23)	4 (15)	109 (15)
Other febrile conditions	15 (6)	29 (9)	8 (19)	2 (7)	3 (12)	2 (8)	59 (8)
Afebrile conditions							
Afebrile diarrheal diseases	5 (2)	7 (2)	2 (5)	0	4 (15)	0	18 (2)
Afebrile eosinophilia	4 (1)	6 (2)	2 (5)	1 (3)	1 (4)	2 (8)	16 (2)
Skin disease	7 (3)	4 (1)	2 (5)	1 (3)	0	0	14 (2)
Afebrile nondiarrheal GI illness	3 (1)	8 (2)	2 (5)	0	0	0	13 (2)
Viral hepatitis	2 (<1)	8 (2)	0	2 (7)	0	0	12 (2)
Leishmaniasis	2 (<1)	0	9 (21)	0	0	0	11 (2)
Giardiasis	0	4 (1)	0	1 (3)	0	0	5 (<1)
Other afebrile	14 (5)	21 (6)	2 (5)	3 (10)	4 (15)	6 (23)	50 (7)
Outcome							
Intensive care unit hospitalization	4 (1)	4 (1)	0	0	2 (8)	1 (4)	11 (2)
Death	1 (<1)	1 (<1)	0	0	0	0	2 (<1)

*Values are no. (%) patients except as indicated. Further details are available in online Technical Appendix Table 1 (<https://wwwnc.cdc.gov/EID/article/24/4/17-1542-Techapp1.pdf>). GI, gastrointestinal; IQR, interquartile range.

†Other comprises case-patients in Oceania (n = 6) and those for whom exact region of infection was undetermined (n = 26).

‡One patient returning from Asia with malaria had a coinfection with *P. falciparum* and *P. vivax*. In this table, we listed the patient under *P. falciparum*.

vs. 1 [3%]); $p < 0.01$); male (81 [94%] vs. 26 [72%]; $p < 0.01$); and to have traveled to middle and western Africa (64 [74%] vs. 0; $p < 0.01$). The annual number of *P. vivax* malaria hospitalizations declined during the study period from an average of 7.3 hospitalizations per year during 2004–2006 to <1 hospitalization per year during 2013–2015 ($R^2 = 0.62$).

Of the 181 acute life-threatening tropical diseases, 86 (48%) were acquired in Africa and 83 (46%) in

Asia (Table 2). Male sex, business travel, and travel to Africa characterized travelers hospitalized for treatment of life-threatening diseases. The most common causes of life-threatening illness requiring hospitalization were *P. falciparum* malaria (86 [48%]) and enteric fever (59 [33%]). Of the 74 cases of dengue fever, none were dengue hemorrhagic fever or dengue shock syndrome; therefore, no dengue cases were considered life-threatening. Eleven (2%) hospitalized travelers required admission to




Figure. Travel-associated hospitalizations of citizens of Israel at Sheba Medical Center, Israel, by country of disease acquisition (A), and estimated number of Israeli citizen entries to each country (B), 2004–2005. Data on Israeli citizen entries from the United Nations World Tourism Organization (4). DRC, Democratic Republic of the Congo; PNG, Papua New Guinea.

an intensive care unit, and 2 of these patients died during their hospitalization. One patient died from endocarditis caused by *Staphylococcus aureus* and 1 from necrotizing fasciitis in a surgical wound while hospitalized for eosinophilia and abdominal mass.

A total of 112 (16%) hospitalizations were potentially preventable by chemoprophylaxis or pretravel vaccination: *P. falciparum* malaria (86, 12%); *Salmonella enterica* serovar Typhi (23, 3%); hepatitis A (2, <1%); and acute hepatitis B (1, <1%). Most of the life-threatening diseases

acquired in Africa were potentially preventable (84, 98%); significantly fewer (25, 30%) from Asia were potentially preventable ($p < 0.01$).

Conclusions

We reviewed >700 posttravel hospitalizations of citizens in Israel during 2004–2015. Acute, life-threatening illnesses necessitated 25% of admissions, most of which were potentially preventable by malaria chemoprophylaxis or pretravel vaccination. Compared with other regions,

Table 2. Comparison of characteristics of travelers hospitalized for treatment of acute life-threatening tropical diseases and those with non-life-threatening illnesses, Sheba Medical Center, Israel, 2004–2015*

Patient characteristics	Life-threatening illness, † n = 181	Non-life-threatening illness, n = 541	p value
Male sex	145 (81)	385 (71)	0.02
Age, median (IQR)	33 (25–49)	33 (25–50)	0.62
Elderly, age ≥60 y	15 (8)	68 (13)	0.12
Category of travelers			
Tourism	138 (76)	448 (83)	0.05
Business travelers	43 (24)	73 (13)	<0.01
Visiting friends or relatives	0 (0)	20 (3)	<0.01
Continent of travel			
Africa	86 (48)	181 (33)	<0.01
Asia	83 (46)	247 (46)	0.98
South America	0	43 (8)	<0.01
Central America and Caribbean	8 (4)	22 (4)	0.83
North America and Europe	1 (<1)	25 (5)	<0.01
Other‡	3 (2)	23 (4)	0.11

*Values are no. (%) patients except as indicated. IQR, interquartile range.

†Life-threatening diseases (n = 181): *P. falciparum* (86), *S. enterica* ser. Paratyphi (36), leptospirosis (29), *S. enterica* ser. Typhi (23), rickettsial diseases (3), melioidosis (2), hantavirus (1), trypanosomiasis (1).

‡Other comprises Oceania (n = 6) and cases whose exact region of infection was undetermined (n = 26).

nearly all life-threatening diseases in travelers returning from Africa were preventable.

Most travelers who were admitted to hospitals to treat preventable life-threatening diseases after returning from Africa were diagnosed with *P. falciparum* malaria. The number of *P. vivax* malaria hospitalizations declined during the study years, possibly related to discontinuation of rafting trips to the Omo River in Ethiopia, which had resulted a high number of infections in earlier years. In travelers returning from Asia, enteric fever was the second most common cause of hospitalization, after dengue fever; *S. enterica* ser. Paratyphi, for which an effective vaccine is not available, caused most of those illnesses. An outbreak of *Salmonella* Paratyphi A enteric fever in Nepal (5) may have contributed to this trend.

Our study has several limitations. SMC is the national referral center for travel-related illness; therefore, an unusually high number of severe or complicated illnesses may have affected our results. Because of the relatively small number of hospitalizations related to individual destination countries, singular events or large outbreaks may have biased the country-specific data (5). The Israeli traveler population is generally characterized by a low rate of travelers visiting friends and relatives, except travelers to Ethiopia. Approximately one third of the patients hospitalized after travel to Ethiopia were born in Ethiopia or born to parents from Ethiopia who immigrated to Israel. This relationship may have resulted in a higher posttravel hospitalization number among citizens of Israel returning from Ethiopia, because travelers visiting friends and relatives may be at a higher risk (6). Because of the different methods of traveler data capture used by different countries reporting to the United Nations World Tourism Organization, our use of the reported number of Israeli citizen entries from this dataset was limited to contextualize the number of hospitalizations from specific countries in relative terms, rather than to calculate country-specific rates of hospitalization.

In conclusion, Israeli citizens hospitalized to treat life-threatening diseases after returning from travel to Africa were likely to suffer from preventable illnesses. Knowledge

of region-specific hospitalization causes and impact should be used to identify at-risk travelers, enhance pretravel preparation, and advocate adherence to recommended vaccines and malaria prophylaxis.

About the Author

Dr. Avni is a medical intern at The Chaim Sheba Medical Center, Tel Hashomer, Israel. His research interests include infectious diseases, tropical diseases, travel medicine, and epidemiology.

References

1. Ryan ET, Wilson ME, Kain KC. Illness after international travel. *N Engl J Med*. 2002;347:505–16. <http://dx.doi.org/10.1056/NEJMra020118>
2. Leder K, Torresi J, Libman MD, Cramer JP, Castelli F, Schlagenhauf P, et al.; GeoSentinel Surveillance Network. GeoSentinel surveillance of illness in returned travelers, 2007–2011. *Ann Intern Med*. 2013;158:456–68. <http://dx.doi.org/10.7326/0003-4819-158-6-201303190-00005>
3. Jensenius M, Han PV, Schlagenhauf P, Schwartz E, Parola P, Castelli F, et al.; GeoSentinel Surveillance Network. Acute and potentially life-threatening tropical diseases in western travelers—a GeoSentinel multicenter study, 1996–2011. *Am J Trop Med Hyg*. 2013;88:397–404. <http://dx.doi.org/10.4269/ajtmh.12-0551>
4. United Nations World Tourism Organization. Israel: country-specific: outbound tourism 1995–2016 (12.2017). Tourism statistics. 2017 [cited 2018 Mar 12]. <http://www.e-unwto.org/doi/abs/10.5555/unwtotfb0376250119952016201712>
5. Meltzer E, Stienlauf S, Leshem E, Sidi Y, Schwartz E. A large outbreak of *Salmonella paratyphi* A infection among Israeli travelers to Nepal. *Clin Infect Dis*. 2014;58:359–64. <http://dx.doi.org/10.1093/cid/cit723>
6. Ericsson CD, Hatz C, Leder K, Tong S, Weld L, Kain KC, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. *Clin Infect Dis*. 2006;43:1185–93. <http://dx.doi.org/10.1086/507893>

Address for correspondence: Eli Schwartz, Center of Geographic Medicine, The Chaim Sheba Medical Center, Tel Hashomer 52621, Israel; email: elischwa@post.tau.ac.il; Eyal Leshem, Infectious Diseases Unit, The Chaim Sheba Medical Center, Tel Hashomer 52621, Israel; email: leshem@gmail.com

Preventable Region-Specific Life-Threatening Diseases among Israeli International Travelers, 2004–2015

Technical Appendix

Technical Appendix Table 1 contains detailed information on all travel-associated hospitalizations included in the present study by region of travel.

In the description of causes of hospitalization acquired in a single destination country in Technical Appendix Table 2, we included travelers for whom the country of disease acquisition was determinable (634/722, 88%). We excluded countries in which <5 hospitalizations were recorded during the study years. Only countries with consistent entries reporting and ≥ 5 hospitalizations are shown (Technical Appendix Table 2).

We extracted the total number of Israeli citizen entries for each destination country during 2004–2015 from the United Nations World Tourism Organization dataset (1). In some countries, reporting of Israeli entries was inconsistent (i.e., there were years with missing entry data). Countries with consistent entry reporting were defined as countries which reported the number of Israeli citizen entries during all years or at least 11 out of 12 years included in the study. We included all countries with ≥ 5 hospitalizations regardless of whether they consistently reported to the United Nations World Tourism Organization; and when reporting was inconsistent, we denote as non-applicable (NA) for number of entries.

Technical Appendix Table 1. Travel-associated hospitalizations at Sheba Medical Center, Israel 2004–2015 (N = 722)*†

Category	Africa n = 267 (%)	Asia n = 330 (%)	South America n = 43 (%)	Central America and the Caribbean n = 30 (%)	North America and Europe n = 26 (%)	Other§ n = 26 (%)	Total N = 722 (%)
Patient characteristics							
Sex, male	226 (85)	219 (66)	28 (65)	20 (67)	21 (81)	16 (62)	530 (73)
Age, median (IQR)	41 (29–53)	29 (24–43)	24 (23–43)	29 (27–46)	55 (39–64)	27 (23–41)	33 (26–50)
Elderly, age ≥ 60 y	37 (14)	27 (8)	4 (9)	3 (10)	8 (31)	4 (15)	83 (11)
Category of travelers							
Tourism	154 (58)	313 (95)	41 (95)	29 (97)	23 (88)	26 (100)	586 (81)
Business travelers	93 (35)	17 (5)	2 (5)	1 (3)	3 (12)	0 (0)	116 (16)
VFR	19 (7)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	20 (3)

Category	Africa	Asia	South America	Central America and the Caribbean	North America and Europe	Other§	Total
	n = 267 (%)	n = 330 (%)	n = 43 (%)	n = 30 (%)	n = 26 (%)	n = 26 (%)	N = 722 (%)
Type of illness							
Potentially preventable	85 (32)	25 (8)	0 (0)	1 (3)	0 (0)	1 (4)	112 (16)
Febrile							
Unspecified febrile illness	34 (13)	55 (17)	7 (16)	3 (10)	6 (23)	4 (15)	109 (15)
Malaria							
<i>P. falciparum</i> ‡	82 (30)	4 (1)	0 (0)	0 (0)	0 (0)	0 (0)	86 (12)
<i>P. vivax</i>	23 (9)	7 (2)	3 (7)	0 (0)	0 (0)	3 (12)	36 (5)
<i>P. ovale</i>	8 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	8 (1)
<i>P. malariae</i>	7 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (<1)
Unidentified malaria	6 (2)	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	8 (1)
Dengue fever	4 (1)	59 (18)	2 (5)	8 (27)	0 (0)	1 (4)	74 (10)
Enteric fever							
<i>S. enterica</i> ser. Typhi	2 (<1)	19 (6)	0 (0)	1 (3)	0 (0)	1 (4)	23 (3)
<i>S. enterica</i> ser. Paratyphi	0 (0)	36 (11)	0 (0)	0 (0)	0 (0)	0 (0)	36 (5)
Leptospirosis	1 (<1)	18 (5)	0 (0)	7 (23)	1 (4)	2 (8)	29 (4)
Pneumonia	10 (4)	11 (3)	0 (0)	1 (3)	5 (19)	1 (4)	28 (4)
Febrile diarrheal diseases							
Febrile diarrhea	7 (3)	4 (1)	0 (0)	0 (0)	0 (0)	1 (4)	12 (2)
Febrile gastroenteritis	2 (<1)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	3 (<1)
<i>Shigella sonnei</i>	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Febrile dysentery	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	1 (<1)
<i>Campylobacter jejuni</i>	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (<1)
Febrile non-diarrheal GI	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)	1 (<1)	3 (<1)
Acute schistosomiasis	16 (6)	3 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	19 (3)
Influenza	0 (0)	7 (2)	0 (0)	0 (0)	0 (0)	1 (4)	8 (1)
Epstein-Barr virus	1 (<1)	6 (2)	1 (2)	0 (0)	0 (0)	0 (0)	8 (1)
Cytomegalovirus	4 (1)	2 (<1)	2 (5)	0 (0)	0 (0)	0 (0)	8 (1)
Ameobic liver abscess	0 (0)	5 (2)	0 (0)	0 (0)	0 (0)	2 (8)	7 (<1)
Rickettsial diseases	3 (1)	3 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	6 (<1)
Upper respiratory tract infection	4 (1)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	5 (<1)
Pyelonephritis	1 (<1)	3 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	4 (<1)
Histoplasmosis	0 (0)	0 (0)	2 (5)	2 (7)	0 (0)	0 (0)	4 (<1)
Meningitis	2 (<1)	0 (0)	2 (5)	0 (0)	0 (0)	0 (0)	4 (<1)
Febrile eosinophilia	0 (0)	2 (<1)	1 (2)	0 (0)	0 (0)	0 (0)	3 (<1)
Endocarditis	1 (<1)	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	3 (<1)
Legionella	1 (<1)	1 (<1)	0 (0)	0 (0)	1 (4)	0 (0)	3 (<1)
Febrile cellulitis	1 (<1)	1 (<1)	1 (2)	0 (0)	0 (0)	0 (0)	3 (<1)
Encephalitis	0 (0)	2 (<1)	0 (0)	0 (0)	1 (4)	0 (0)	3 (<1)
Brucella	1 (<1)	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	3 (<1)
<i>Coxiella burnetii</i>	3 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (<1)
Tuberculosis	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
HIV	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	1 (<1)
Other febrile							
Chikungunya	0 (0)	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Melioidosis	0 (0)	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Herpes Simplex virus 1 (HSV1)	0 (0)	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Untyped infectious mononucleosis	0 (0)	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Pericarditis	0 (0)	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Ross River Fever	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (<1)
Hantavirus	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Trypanosomiasis	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Febrile infected wound	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (<1)
Respiratory Syncytial virus	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Bronchitis	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Meningoencephalitis	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Meningoencephalitis d/t HSV2	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Myocarditis	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (<1)
Febrile inflammatory bowel disease	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Afebrile conditions							
Afebrile diarrheal diseases							
Afebrile diarrhea	3 (1)	7 (2)	2 (5)	0 (0)	2 (8)	0 (0)	14 (2)
Afebrile gastroenteritis	1 (<1)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	2 (<1)
Afebrile dysentery	1 (<1)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	2 (<1)

Category	Africa	Asia	South America	Central America and the Caribbean	North America and Europe	Other§	Total
	n = 267 (%)	n = 330 (%)	n = 43 (%)	n = 30 (%)	n = 26 (%)	n = 26 (%)	N = 722 (%)
Afebrile eosinophilia	4 (1)	6 (2)	2 (5)	1 (3)	1 (4)	2 (8)	16 (2)
Skin disease							
Afebrile cellulitis	3 (1)	2 (<1)	0 (0)	1 (3)	0 (0)	0 (0)	6 (<1)
Rash	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Skin ulcer	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Afebrile infected wound	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Pyoderma	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Urticaria	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (<1)
Miyasis	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (<1)
Afebrile non-diarrheal GI							
Afebrile abdominal pain	2 (<1)	5 (2)	2 (5)	0 (0)	0 (0)	0 (0)	9 (1)
Other GI symptoms	0 (0)	3 (1)	0 (0)	0 (0)	0 (0)	0 (0)	3 (<1)
Vomiting alone	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Viral hepatitis	2 (<1)	8 (2)	0 (0)	2 (7)	0 (0)	0 (0)	12 (2)
Leishmaniasis	2 (<1)	0 (0)	9 (21)	0 (0)	0 (0)	0 (0)	11 (2)
Giardiasis	0 (0)	4 (1)	0 (0)	1 (3)	0 (0)	0 (0)	5 (<1)
Neurocysticercosis	1 (<1)	3 (1)	0 (0)	0 (0)	0 (0)	0 (0)	4 (<1)
Filariasis	4 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (<1)
Lymphadenopathy	1 (<1)	2 (<1)	0 (0)	0 (0)	0 (0)	1 (4)	4 (<1)
Deep vein thrombosis	0 (0)	1 (<1)	0 (0)	1 (3)	1 (4)	0 (0)	3 (<1)
Reactive arthritis	0 (0)	0 (0)	1 (2)	1 (3)	1 (4)	0 (0)	3 (<1)
Strongyloides	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	2 (8)	3 (<1)
Other afebrile							
Onchocerciasis	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Pulmonary embolism	0 (0)	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Afebrile Inflammatory bowel disease	1 (<1)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	2 (<1)
Cough	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)
Chest pain	1 (<1)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (<1)
Anemia	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Henoch-Schonlein Purpura	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Seizure	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
<i>Helicobacter pylori</i>	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (<1)
Furunculosis	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Afebrile URTI	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Trauma	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Muscle weakness	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (<1)
Appendicitis	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	1 (<1)
Fatigue	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Renal failure	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Rheumatoid arthritis	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Leg pain	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Abdominal mass w eosinophilia	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Idiopathic thrombocytopenic purpura	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Tropical splenomegaly	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Coccidiosis	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	1 (<1)
Echinococcosis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (<1)
Unidentified helminth	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)
Outcome							
Intensive care unit hospitalization	4 (1)	4 (1)	0 (0)	0 (0)	2 (8)	1 (4)	11 (2%)
Mortality	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1%)

*IQR, interquartile range; VFR, visiting friends or relatives; URTI, upper respiratory tract infection; GI, gastrointestinal.

†Values are no. (%) except as indicated.

‡One patient returning from Asia with malaria had a coinfection with both *P. falciparum* and *P. vivax*. In this case, we decided to list the patient under *P. falciparum*.

§"Other" comprises both Oceania (n = 6) and cases whose exact region of infection was undetermined (n = 26).

Technical Appendix Table 2. Number of hospitalized Israeli travelers at Sheba Medical Center by destination country and United Nations World Tourism Organization estimates of Israeli traveler entries to the destination country, 2004–2015 (n = 535)*†.

Continent	Country§	Number of hospitalizations	Israeli entries to country	Most common cause of hospitalization
Africa	Ethiopia‡	48	92,839	<i>Plasmodium vivax</i> (n = 21, 44%)
	Angola‡	38	28,862	<i>Plasmodium falciparum</i> (n = 16, 42%)
	Equatorial Guinea	33	NA	<i>Plasmodium falciparum</i> (n = 19, 58%)
	Nigeria	24	225,824	<i>Plasmodium falciparum</i> (n = 9, 38%)
	Tanzania, United Republic of	16	52,651	Schistosomiasis (n = 4, 25%),
	Uganda	15	14,786	<i>Plasmodium falciparum</i> (n = 6, 40%)
	Congo, Democratic Republic of the	12	24,464	<i>Plasmodium falciparum</i> (n = 4, 33%)
	Sierra Leone	8	1,644	<i>Plasmodium falciparum</i> (n = 4, 50%)
	Ghana	8	NA	Diarrhea (n = 3, 38%)
	Liberia	7	NA	<i>Plasmodium falciparum</i> (n = 5, 71%)
Asia	India	116	542,915	Dengue fever (n = 17, 15%)
	Thailand	106	1,410,957	Dengue fever (n = 36, 34%)
	Nepal	37	72,025	<i>S. enterica</i> ser. Paratyphi (n = 23, 62%)
	China	12	1,329,533	Unspecified febrile disease (n = 2, 17%)
	Lao People's Democratic Republic	8	45,465	Leptospirosis (n = 4, 50%)
Americas	Bolivia	9	NA	<i>Leishmania braziliensis</i> (n = 9, 100%)
	Guatemala	8	NA	Leptospirosis (n = 4, 50%)
	Costa Rica	7	125,237	Leptospirosis (n = 4, 57%)
	Peru	7	144,427	Afebrile non-diarrheal GI (n = 2, 29%) Cytomegalovirus (n = 2, 29%)
	United States	6	3,799,836	Single cases of deep vein thrombosis, encephalitis, Coccidiosis, gastroenteritis, pneumonia, leptospirosis.
	Brazil	5	410,326	Unspecified febrile disease (n = 2, 40%)
Oceania	Papua New Guinea	5	2,047	Leptospirosis (n = 2, 40%) <i>Plasmodium vivax</i> (n = 2, 40%)

*UNWTO, United Nations World Tourism Organization (1); NA, not applicable.

†Included are all countries with ≥5 hospitalizations regardless of whether they consistently reported to UNWTO; when reporting was inconsistent, we denote NA for number of entries.

‡For Angola and Ethiopia, one year of Israeli citizen entry data was missing. Assuming the number of entries did not change substantially during the missing year, we used the average number of entries during all other years as the number of entries during in the missing year.

§Countries that officially forbid entry of Israeli citizens: Algeria, Bangladesh, Brunei, Iran, Iraq, Kuwait, Lebanon, Libya, Malaysia, Oman, Pakistan, Saudi Arabia, Sudan, Syria, United Arab Emirates, Yemen.

Reference

1. United Nations World Tourism Organization. Israel: Country-specific: Outbound tourism 1995–2016 (12.2017). Tourism statistics. 2017. <http://www.e-unwto.org/doi/abs/10.5555/unwtotfb0376250119952016201712>